knowledge -WSS

knowledge

author：explore 2025-10-01 01:50:00 - browse：62944

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Mark Cuban is blaming the wrong people for high drug costs

hotspot

WSS

Organ aging and disease risk measured by new blood test

What don’t we know about an Alzheimer’s drug side effect?

Organ aging and disease risk measured by new blood test

Schizophrenia gene found to be linked to cells' energy dysfunction

Megan Rapinoe shares emotional post following US Women's World Cup exit

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Affirmative action in medical school literally saved lives

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

U.K. Biobank has 500,000 peoples' genome sequences available

United colonoscopy coverage change 'may cost lives,' doctors say

Illumina slashes 2023 revenue projections yet again

The high cost of giving birth even with insurance

Senators push IRS to launch nonprofit hospital probe

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

hotspot

30 years of 'Listening to Prozac'

Timeline: How the deadly wildfires took over Maui day by day

Surge in Apellis stock fueled by confidence in safety of its eye drug

Mark Cuban is blaming the wrong people for high drug costs

CDC director unscathed in first congressional testimony

Mayo Clinic plans $5B tech

entertainment

hotspot

hotspot

focus